Live attenuated vaccines under immunosuppressive agents or biological agents: survey and clinical data from Japan

Kamei, Koichi; Miyairi, Isao; Shoji, Kensuke; Arai, Katsuhiro; Kawai, Toshinao; Ogura, Masao; Ishikura, Kenji; Sako, Mayumi; Nakamura, Hidefumi

doi:10.1007/s00431-021-03927-1

Cited by 4 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To enable the future use in society of live attenuated vaccines in patients receiving immunosuppressants, we conducted a national survey with the aim of revising the wording “contraindicated” on package inserts [ 44 ]. The primary survey was an institutional survey in which questionnaires were mailed to 480 institutions, receiving and analyzing responses from 415 institutions (86.5%).…”

Section: National Survey On Live Attenuated Vaccines In Patients Usin...mentioning

confidence: 99%

Live attenuated vaccines in patients receiving immunosuppressive agents

Kamei

2023

Pediatr Nephrol

Self Cite

View full text Add to dashboard Cite

The use of live attenuated vaccines in patients with immunosuppressive agents is contraindicated in package inserts and guidelines in Japan and other countries. However, patients receiving immunosuppressants have a high risk of infectious disease becoming severe, and the necessity to prevent infectious disease is high. To date, 2,091 vaccinations have been reported in 25 reports of live attenuated vaccines in people receiving immunosuppressants. Twenty-three patients (1.1%) became infected with the virus strain used in the vaccine, which was varicella virus in 21 patients. No reports have described life-threatening complications. A prospective study at the National Center for Child Health and Development conducted under certain immunological conditions (CD4 cell count ≥ 500/mm 3 , stimulation index of lymphocyte blast transformation by phytohemagglutinin (PHA) ≥ 101.6, serum immunoglobulin G ≥ 300 mg/dL) confirmed the serological effectiveness and safety. The evidence suggests that live attenuated vaccines can be used even in combination with immunosuppressants. Further evidence must be gathered and immunological criteria investigated to determine the conditions for safe use. Depending on the results of these investigations, the wording in package inserts and guidelines may need to be revised.

show abstract

Section: National Survey On Live Attenuated Vaccines In Patients Usin...mentioning

confidence: 99%

Live attenuated vaccines in patients receiving immunosuppressive agents

Kamei

2023

Pediatr Nephrol

Self Cite

View full text Add to dashboard Cite

show abstract

Immunosuppressants/varicella zoster virus vaccine live

2022

Reactions Weekly

View full text Add to dashboard Cite

Bordetella bronchiseptica and Bordetella pertussis: Similarities and Differences in Infection, Immuno-Modulation, and Vaccine Considerations

et al. 2023

View full text Add to dashboard Cite

Bordetella pertussis and Bordetella bronchiseptica belong to the genus Bordetella , which comprises 14 other species. B. pertussis is responsible for whooping cough in humans, a severe infection in children and less severe or chronic in adults. These infections are restricted to humans and currently increasing worldwide. B. bronchiseptica is involved in diverse respiratory infections in a wide range of mammals.

show abstract

Live attenuated vaccines under immunosuppressive agents or biological agents: survey and clinical data from Japan

Cited by 4 publications

References 23 publications

Live attenuated vaccines in patients receiving immunosuppressive agents

Live attenuated vaccines in patients receiving immunosuppressive agents

Immunosuppressants/varicella zoster virus vaccine live

Bordetella bronchiseptica and Bordetella pertussis: Similarities and Differences in Infection, Immuno-Modulation, and Vaccine Considerations

Contact Info

Product

Resources

About